Table 2.
Prevalence and levels of potential drug–drug interactions (pDDIs) in chronic kidney disease patients
| Type of prevalence | Patient, n (%) | Levels | Frequency, n (%) |
|---|---|---|---|
| Overall prevalencea | 164 (78.5) | Total pDDIs | 541 (100.0) |
| Severity of pDDIsb | Severity | ||
| Contraindicated | 28 (13.4) | Contraindicated | 30 (5.5) |
| Major | 58 (27.8) | Major | 75 (13.9) |
| Moderate | 127 (60.8) | Moderate | 306 (56.6) |
| Minor | 86 (41.1) | Minor | 130 (24.0) |
| Number of pDDIs per patient | Evidence | ||
| 1–2 | 81 (38.8) | Excellent | 34 (6.3) |
| 3–5 | 58 (27.8) | Good | 267 (49.4) |
| ≥6 | 25 (12.0) | Fair | 240 (44.3) |
| Median | 3 | Onset | |
| Range | 1–22 | Rapid | 187 (34.6) |
| Total pDDIs | 541 | Delayed | 192 (35.5) |
| Not specified | 163 (29.9) | ||
Notes:
a
Overall prevalence means the presence of at least one pDDI regardless of severity type;
b
percentages do not add up to 78.5% because many patients were exposed to multiple pDDIs of different severities.